Clinical trial
The ReInforcement of Adherence Via Self-monitoring App Orchestrating Biosignals and Medication of RivoXaban in Patients With Atrial Fibrillation and Co-morbidities: Randomised Control Study(RIVOX-AF Study)
NCT05557123 is registered in ClinicalTrials.gov with Seoul National University Bundang Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The ReInforcement of Adherence Via Self-monitoring App Orchestrating Biosignals and Medication of RivoXaban in Patients With Atrial Fibrillation and Co-morbidities: Randomised Control Study(RIVOX-AF Study)
- Lead sponsor
- Seoul National University Bundang Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 10, 2022
- Completion date
- December 16, 2025
- Enrollment
- 637 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.